NPI: 1558765529 · KINGS MOUNTAIN, NC 28086 · General Acute Care Hospital · NPI assigned 10/20/2014
Authorized official DEFURIO, ANTHONY controls 19+ related entities in our dataset. Read more
| Authorized Official | DEFURIO, ANTHONY (EXECTUVIE VICE PRESIDENT/CFO) |
| NPI Enumeration Date | 10/20/2014 |
Other providers sharing the same authorized official: DEFURIO, ANTHONY
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 25,339 | $1.53M |
| 2019 | 13,606 | $1.08M |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 99283 | Emergency department visit for the evaluation and management, moderate severity | 9,129 | 8,464 | $1.10M |
| 99284 | Emergency department visit for the evaluation and management, high severity | 5,578 | 5,119 | $777K |
| 41899 | Unlisted procedure, dentoalveolar structures | 356 | 334 | $459K |
| J3490 | Unclassified drugs | 9,494 | 6,158 | $71K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1,152 | 1,067 | $45K |
| 99285 | Emergency department visit for the evaluation and management, high severity with immediate threat to life | 349 | 319 | $44K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 2,726 | 2,531 | $37K |
| 80047 | 1,553 | 1,397 | $16K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 886 | 817 | $10K |
| 81001 | 3,010 | 2,793 | $9K | |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 47 | 46 | $5K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 175 | 168 | $5K |
| 27096 | 50 | 49 | $3K | |
| 81025 | 482 | 431 | $3K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 462 | 447 | $3K |
| 87086 | Culture, bacterial; quantitative colony count, urine | 188 | 166 | $2K |
| 71046 | Radiologic examination, chest; 2 views | 92 | 87 | $2K |
| 80053 | Comprehensive metabolic panel | 58 | 58 | $2K |
| 62323 | 14 | 14 | $1K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 377 | 356 | $1K |
| 85027 | 272 | 249 | $1K | |
| 96375 | Therapeutic injection; each additional sequential IV push | 231 | 197 | $999.27 |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 72 | 65 | $994.40 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 349 | 328 | $686.51 |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | 419 | 393 | $577.72 |
| J2704 | Injection, propofol, 10 mg | 350 | 328 | $538.58 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 338 | 316 | $532.56 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 182 | 180 | $339.01 |
| 71045 | Radiologic examination, chest; single view | 30 | 28 | $302.53 |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 15 | 14 | $271.50 |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 14 | 14 | $252.14 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 215 | 209 | $236.37 |
| 80048 | Basic metabolic panel (calcium, ionized) | 13 | 13 | $109.89 |
| J1030 | Injection, methylprednisolone acetate, 40 mg | 99 | 99 | $93.49 |
| 84484 | 14 | 13 | $73.56 | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 14 | 13 | $58.96 |
| 85014 | 15 | 15 | $56.15 | |
| 96361 | Intravenous infusion, hydration; each additional hour | 12 | 12 | $35.10 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 14 | 14 | $27.75 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 75 | 74 | $24.23 |
| J8540 | Dexamethasone, oral, 0.25 mg | 12 | 12 | $9.05 |
| 82962 | 12 | 12 | $2.92 |